Latest news with #EdisonSystem
Yahoo
4 days ago
- Business
- Yahoo
HistoSonics announces acquisition by investor consortium for $2.25bn
HistoSonics has announced a substantial management-led majority stake acquisition by a consortium of investors, including public and private entities, with a transaction that values the company at around $2.25bn. This strategic move is set to expedite the company's growth and facilitate the expansion of the Edison Histotripsy System into new clinical indications and markets, according to a company release. The company will continue under the leadership of CEO and president Mike Blue, alongside his executive team. Blue will also become the chairman of the board on the closing of the transaction. Blue said: 'This new group of partners backs category-defining companies that transform entire industries. 'Their support gives us the firepower to accelerate our momentum, expand into new clinical indications, and reach even more patients around the world who urgently need our breakthrough therapy.' The deal enables HistoSonics to broaden its therapeutic reach, targeting not only liver tumours but also pancreas, prostate, and kidney conditions. Established in 2009, the company envisions a future where histotripsy can be applied to a wide array of clinical applications, treating both benign and malignant conditions. The Edison system has reportedly been used to treat over 2,000 individuals at more than 50 US medical centres so far, with plans to install another 50 systems by the year's end. The system is intended for the non-invasive destruction of liver tumours, including unresectable liver tumours, leveraging a non-thermal, mechanical process of focused ultrasound. In October 2023, the company secured marketing authorisation from the US Food and Drug Administration (FDA) for its Edison histotripsy platform. The company is backed by preclinical and clinical research across several organ systems. HistoSonics is actively enrolling subjects in clinical trials for kidney, liver, and pancreas tumours, with further trials slated to begin shortly. The investment syndicate features Bezos Expeditions, K5 Global, and Wellington Management, along with Alpha JWC Ventures and other existing investors such as Venture Investors Health Fund and Alpha Wave Ventures. Lumira Ventures and Early Stage Partners are also part of the investor group. Financial advisory services for HistoSonics were provided by Citi, with Fox Rothschild acting as legal advisers. The investment syndicate was advised by Morgan Stanley & Co and Cooley, with assistance from Orrick while Wilson Sonsini Goodrich & Rosati advised HistoSonics' major existing shareholders. "HistoSonics announces acquisition by investor consortium for $2.25bn" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
5 days ago
- Business
- Business Upturn
HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors
Business Wire India HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced a management-led majority stake acquisition by a syndicate of globally recognized private and public investors, including K5 Global, Bezos Expeditions, Wellington Management and other new and existing investors. The transaction values HistoSonics at approximately $2.25 billion and positions the company for accelerated growth of the Edison System across new clinical indications and global markets. This press release features multimedia. View the full release here: HistoSonics Non-Invasive Edison Histotripsy System Image credit: HistoSonics HistoSonics will continue to be led by President and Chief Executive Officer, Mike Blue, and his executive team. Mr. Blue will also assume the role of Chairman of the Board upon closing. 'Our relentless focus as a company has been speed, scale, and the urgency to offer patients a better option than any they have today,' said Mr. Blue. 'This new group of partners backs category-defining companies that transform entire industries. Their support gives us the firepower to accelerate our momentum, expand into new clinical indications, and reach even more patients around the world who urgently need our breakthrough therapy.' HistoSonics plans to expand beyond its initial focus on liver tumors to kidney, pancreas, and prostate indications, with a long-term vision of histotripsy being used across a wide range of clinical applications throughout the body, treating both benign and malignant conditions. 'What stood out with HistoSonics wasn't just the technology, it was the speed and clarity with which the team turned a breakthrough into real clinical traction,' said Bryan Baum, Co-Founder and Managing Partner, K5 Global. 'Hospitals are continuing to order systems, patient demand is surging, and the clinical results speak for themselves. We partnered with HistoSonics because this is one of those rare moments where the science, the execution, and the opportunity all align, and we are here to ensure it reaches every hospital in the world.' HistoSonics, founded in 2009, received FDA De Novo clearance in October 2023 and uses non-invasive focused ultrasound energy to mechanically destroy and liquify targeted tissue and tumors at a sub-cellular level and without the invasiveness or toxicity of traditional procedures. To date, over 2,000 patients have been treated by the Edison system at over 50 leading U.S. medical centers, with another 50 planned system installations by year-end. Supported by extensive preclinical and clinical research across multiple organ systems, including liver, kidney, pancreas, prostate and others, the company is currently enrolling patients in clinical trials for liver tumors, kidney tumors (HOPE4KIDNEY Trial NCT05820087) and pancreas tumors (GANNON Trial NCT06282809), with plans to start others in the near future. Additional participants in the transaction include top‑tier global investment firms, including Alpha JWC Ventures, alongside existing investors Alpha Wave Ventures, Venture Investors Health Fund, Lumira Ventures, Hatteras Venture Partners, Early Stage Partners, Amzak Health, HealthQuest Capital, Yonjin Venture, the State of Wisconsin Investment Board, the State of Michigan Retirement System, Johnson & Johnson through its corporate venture capital organization, Johnson & Johnson – JJDC, Inc. (JJDC), and others. Citi served as financial advisor and Fox Rothschild served as legal advisor to HistoSonics. Morgan Stanley & Co. LLC served as financial advisor and Cooley, with assistance from Orrick, served as legal advisors to the investment syndicate. Wilson Sonsini Goodrich & Rosati served as legal advisor to Histosonics' existing major shareholders. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, MI and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit: View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
5 days ago
- Business
- Business Wire
HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors
MINNEAPOLIS--(BUSINESS WIRE)-- HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced a management-led majority stake acquisition by a syndicate of globally recognized private and public investors, including K5 Global, Bezos Expeditions, Wellington Management and other new and existing investors. The transaction values HistoSonics at approximately $2.25 billion and positions the company for accelerated growth of the Edison System across new clinical indications and global markets. HistoSonics will continue to be led by President and Chief Executive Officer, Mike Blue, and his executive team. Mr. Blue will also assume the role of Chairman of the Board upon closing. 'Our relentless focus as a company has been speed, scale, and the urgency to offer patients a better option than any they have today,' said Mr. Blue. 'This new group of partners backs category-defining companies that transform entire industries. Their support gives us the firepower to accelerate our momentum, expand into new clinical indications, and reach even more patients around the world who urgently need our breakthrough therapy.' HistoSonics plans to expand beyond its initial focus on liver tumors to kidney, pancreas, and prostate indications, with a long-term vision of histotripsy being used across a wide range of clinical applications throughout the body, treating both benign and malignant conditions. 'What stood out with HistoSonics wasn't just the technology, it was the speed and clarity with which the team turned a breakthrough into real clinical traction,' said Bryan Baum, Co-Founder and Managing Partner, K5 Global. 'Hospitals are continuing to order systems, patient demand is surging, and the clinical results speak for themselves. We partnered with HistoSonics because this is one of those rare moments where the science, the execution, and the opportunity all align, and we are here to ensure it reaches every hospital in the world.' HistoSonics, founded in 2009, received FDA De Novo clearance in October 2023 and uses non-invasive focused ultrasound energy to mechanically destroy and liquify targeted tissue and tumors at a sub-cellular level and without the invasiveness or toxicity of traditional procedures. To date, over 2,000 patients have been treated by the Edison system at over 50 leading U.S. medical centers, with another 50 planned system installations by year-end. Supported by extensive preclinical and clinical research across multiple organ systems, including liver, kidney, pancreas, prostate and others, the company is currently enrolling patients in clinical trials for liver tumors, kidney tumors (HOPE4KIDNEY Trial NCT05820087) and pancreas tumors (GANNON Trial NCT06282809), with plans to start others in the near future. Additional participants in the transaction include top‑tier global investment firms, including Alpha JWC Ventures, alongside existing investors Alpha Wave Ventures, Venture Investors Health Fund, Lumira Ventures, Hatteras Venture Partners, Early Stage Partners, Amzak Health, HealthQuest Capital, Yonjin Venture, the State of Wisconsin Investment Board, the State of Michigan Retirement System, Johnson & Johnson through its corporate venture capital organization, Johnson & Johnson - JJDC, Inc. (JJDC), and others. Citi served as financial advisor and Fox Rothschild served as legal advisor to HistoSonics. Morgan Stanley & Co. LLC served as financial advisor and Cooley, with assistance from Orrick, served as legal advisors to the investment syndicate. Wilson Sonsini Goodrich & Rosati served as legal advisor to Histosonics' existing major shareholders. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, MI and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit:
Business Wire
16-07-2025
- Business
- Business Wire
Proximie and HistoSonics Sign U.S. Partnership to Revolutionize Treatment of Liver Tumors
BOSTON--(BUSINESS WIRE)--Proximie (the 'Company'), the leading global health technology platform digitizing operating rooms, announces a partnership with HistoSonics, the manufacturer of the Edison ® Histotripsy System 1 and novel histotripsy therapy platforms used for non-invasive treatment of liver tumors. Dividends for surgeons and clinical teams are multiple: increased productivity; access to operational best practices; medical innovation, and improved patient outcomes. The U.S.-focused partnership demonstrates the value Proximie's cloud-based operating system designed for intelligent ORs offers to medical device companies, as the Company enhances the adoption and user experience of HistoSonics' Edison System. Proximie's OR intelligence platform offers a tailored digital ecosystem which drives healthcare innovation. The platform facilitates real-time connectivity; unified data – including data capture, structure, and control capabilities; AI-enabled insight; and a context-rich video library. Within the partnership, Proximie and HistoSonics integrate the Proximie platform and the Edison System to hospitals and ambulatory surgery centers across the U.S., providing significant value for healthcare system operators, physicians, and patients. Specifically, Proximie's real-time connectivity capabilities enable HistoSonics' medical directors and physician faculty to share live expertise to surgeons using the Edison System; treating patients' liver tumors more effectively via focused ultrasound sonic beam therapy; while adding new levels of rapidity to HistoSonic's diagnostics and operations. The dividends for surgeons and clinical teams are multiple: increased productivity; access to operational best practices; medical innovation, and improved patient outcomes. Initial go-live regions for the partnership include Chicago, Colorado, Florida, Louisiana, Seattle, and Southern California. Almost 300,000 patients in the U.S. alone are diagnosed with tumors in the liver, most of which originate from organs outside the liver like the colon, rectum, and pancreas, and travel to the liver. While these metastatic tumors appear in advanced stages, even primary tumors of the liver (Hepatocellular carcinoma) have a dismal 5 year survival rate of less than 18%. With the substantial unmet clinical need from so many tumors in the liver the potential for real-time histotripsy procedural support via Proximie could prove to dramatically impact patient outcomes. Dr. Nadine Hachach-Haram, Founder and CEO of Proximie, commented: 'We are thrilled to announce our partnership with HistoSonics, driving the rollout of the cutting-edge Histotripsy System while making a tangible impact on outcomes for those suffering from liver tumors. The partnership is testament to the benefits of intelligent digital connectivity within the OR; enabled by the Proximie platform; providing value to stakeholders across the healthcare ecosystem.' Mike Blue, President & CEO of HistoSonics, said: 'Our partnership with Proximie represents our commitment to partner with world leaders in their respective domains, providing our customers with the best technology solutions possible. Proximie's ability to provide real-time virtual presence in histotripsy procedures provides opportunities for our medical team to share expertise with physicians across the world and support our customers in unprecedented ways.' The Company's partnership with HistoSonics has already yielded dividends for surgeons and patients. Notably, Dr. Kevin Burns of Providence Mission Hospital has frequently utilized the Proximie platform and the Edison Histotripsy System together, benefiting patients and enabling knowledge-sharing opportunities. Dr. Kevin Burns, Chief of Interventional Radiology at Providence Mission Hospital, said: "HistoSonics' Edison Histotripsy System has drastically improved outcomes for our patients suffering with liver tumors. The system's ability to destroy tumors via non-thermal, non-invasive, personalized therapy significantly reduces recovery times - getting patients out of hospital and back on their feet more quickly, while improving our productivity and operational efficiency. Additionally, the opportunity for clinicians to share live guidance when using the Histotripsy system, via the Proximie platform, is invaluable - ensuring physicians can be confident when performing novel histotripsy therapy for the first time; guaranteeing access to cutting-edge techniques for more patients." The announcement follows recent partnerships between Proximie and numerous global MedTech players. Notably, the Company recently announced a global partnership with Olympus Corporation – the medical technology company and market leader in innovative surgical tools and endoscopy systems; and a partnership with Distalmotion – the surgical robotics pioneer and developer of the Dexter surgical robot. To date, Proximie is deployed across five continents and is working with hundreds of healthcare systems and major medical device developers – creating a truly global impact by improving access to high-quality surgical care in both developed and developing economies. Notes to Editors About Proximie Proximie is a global health technology platform focused on digitizing operating and diagnostic rooms. Proximie's mission is to make surgery more accessible, efficient, and effective for everyone, via cutting-edge, cloud-based technology. Proximie's OR intelligence platform offers a tailored digital ecosystem which drives healthcare innovation. The platform facilitates real-time connectivity, unified data – including data capture, structure, and control capabilities, – AI-enabled insight, and a context-rich video library This provides benefits for the entire healthcare ecosystem via improved productivity, optimized workflows, accelerated training, and enhanced medical technology innovation; benefiting patient outcomes. By opening-up surgery beyond traditional operating room boundaries, Proximie is facilitating a rich, insightful data set which naturally feeds best practices into the entire healthcare ecosystem. Founded by Dr. Nadine Hachach-Haram, Proximie has now been deployed in over 800 hospitals across 50 countries in five continents. Proximie has contracts with over 40 major medical device companies – with access to 90% of operating rooms and diagnostic suites in the U.K., U.S., and EU – and been published in over 20 medical journals. Proximie is the lead author of a report on ' Patient safety in surgery – the urgent need for reform ', highlighting the challenges affecting patient safety in surgery in the NHS as well as potential solutions to improve patient safety. For more information, please visit or follow @Proximie on X and LinkedIn. About HistoSonics HistoSonics is a privately held medical device company developing non-invasive platforms and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, brain, and others. HistoSonics has offices in Ann Arbor, Michigan, and Minneapolis, Minnesota. The Edison ® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any specific disease or condition. Use of the Edison System in kidney applications is limited by federal law to investigational use. The #HOPE4KIDNEY Trial is designed to support a future expansion of the indication to include the destruction of kidney tissue/tumors. 1 HistoSonics' Edison ® Histotripsy System uses proprietary technology and advanced imaging to deliver personalized, non-invasive histotripsy treatments with precision and control. The novel mechanism of action of this proprietary technology may provide significant patient advantages, including the ability of the treatment site to recover and resorb quickly. HistoSonics' platform also provides physicians the ability to monitor the destruction of tissue under continuous real-time visualization and control, unlike any modality that exists today.
Yahoo
10-06-2025
- Health
- Yahoo
Groundbreaking cancer treatment which ‘destroys tumours with sound' to be rolled out on NHS
NHS patients will be the first in Europe to benefit from a pioneering new cancer treatment which uses ultrasound to destroy tumours. The technology, known as histotripsy, offers a non-invasive treatment capable of breaking down liver cancer tissue without surgery, radiation or chemotherapy, with minimal damage to the surrounding organs, according to the Department for Health and Social Care (DHSC). First approved by US regulators in October 2023, histotripsy uses pulsed sound waves to create 'bubble clouds' from gases present in the targeted tissue and tumour. When these bubbles pop, within microseconds, a shockwave is released which is capable of breaking up a mass and killing cancerous cells, while avoiding the harms of radiation and reducing the risks of bleeding, infection, and damage to surrounding non-targeted tissue. Treatment is delivered via a single session – potentially taking just 30 minutes – with limited or no pain, a quick recovery, and can be performed as a day case, according to the DHSC. The first NHS patients are set to be treated this summer at Addenbrooke's Hospital in Cambridge, where the technology – which uses a device called an Edison System, created by US firm HistoSonics – is being debuted after a donation from the Li Ka Shing Foundation. Cancer Research UK describes liver cancer as the 17th most common cancer in the UK and the 8th most frequent cause of cancer death. More than 8,000 people received a new diagnoses in 2022, with liver cancer incidence across the UK having surged by 42 per cent over the past decade, according to the British Liver Trust. So far, more than 1,500 patients worldwide have received treatment using histotripsy, mainly in the United States – following approval by the US Food and Drug Administration in late 2023. According to 12-month follow-up data from HistoSonics' previous clinical trials, which involved patients for whom other treatments had been either unsuccessful or unavailable, overall survival rates after one year were 73.3 per cent for primary liver cancer, and 48.6 per cent for those with secondary tumours. The paper, published in the Annals of Surgery journal in April, noted that both tumour control and survival rates were similar to those among other current treatments. The UK's new device is expected to be fully installed in Cambridge later this year, where it will be used initially to treat patients with primary and secondary liver tumours. Wider research on how this could potentially treat tumours in other organs – such as the pancreas and kidneys – is underway. The technology has been approved in the UK via the innovative devices access pathway, which aims to enable faster approvals of medical devices and treatments which evidence shows are safe, efficient and can fill unmet need. 'This is a strong example of smart, agile regulation in action,' said James Pound, of the Medicines and Healthcare products Regulatory Agency (MHRA). 'It's a major step forward for patients with liver cancer and shows how the UK can be a frontrunner in supporting responsible innovation that meets real clinical need.' While 'regulation is vital to protect patients', the government is 'slashing red tape, so game-changing new treatments reach the NHS front line quicker – transforming healthcare', said health secretary Wes Streeting. Hailing histotripsy as 'an exciting new technology that will make a huge difference to patients', Roland Sinker, chief executive of Cambridge University Hospitals, said: 'By offering this non-invasive, more targeted treatment we can care for more people as outpatients and free up time for surgeons to treat more complex cases. 'The faster recovery times mean patients will be able to return to their normal lives more quickly, which will also reduce pressure on hospital beds, helping us ensure that patients are able to receive the right treatment at the right time.' Fiona Carey, a kidney cancer patient who co-chairs Cambridge's patient advisory group, added: 'This is seriously good news. A new, non-invasive option to treat these cancers is very welcome indeed. 'For patients for whom ordinary surgery is no longer an option, this could make all the difference.'
